《美股業績》渤健(BIIB.US)季績勝預期 新研發阿爾茲海默症藥秋季有測試數據
美國藥廠渤健(Biogen)(BIIB.US)公布第二季業績。季度純利10.58億美元,按年升1.36倍。每股季度攤薄純利7.24美元,經調整後為5.25美元,高於市場預期的4.06美元。季度收入25.89億美元,按年升19%。
公司與日本衛采(Eisai)研發阿爾茲海默症藥物lecanemab料於秋季有測試數據,並已就該藥向美國當局要求加快審批。公司財務總監指,已從自行研發阿爾茲海默症藥Aduhelm事件汲取教訓。Aduhelm早前獲美國批准用作治療阿爾茲海默症,但美國醫保計劃僅針對65歲人士使,Aduhelm藥效亦受質疑。
另外,公司亦同意就多發性硬化藥物向醫生支付回佣指控達成9億美元和解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.